A Roadmap for Personalized Medicine: the findings of the IC2PerMed Project

Author:

Beccia Flavia1,Causio Francesco Andrea1,Marcantonio Marzia Di2,Hoxhaj Ilda3,Cadeddu Chiara4,Campagno Melissa5,Schleicher Lena6,Fotino Carmen7,Tauchert Maike8,Lomazzi Marta9,Wang Lili10,Wang Wenya11,Huang Huiyao12,Ricciardi Walter1,Boccia Stefania1

Affiliation:

1. Section of Hygiene, University Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Rome

2. Faculty of Economics, Università Cattolica del Sacro Cuore, Rome

3. University of Padua

4. Erasmus University Rotterdam

5. G.A.C. Group - Innovation & Performance for Impact

6. Steinbeis Foundation

7. Telethon Foundation

8. Biobanking and Biomolecular Resources Research Infrastructure - ERIC

9. World Federation of Public Health Associations

10. Jingyi Alliance Clinical Application; BGI

11. Tsinghua University

12. Academic Director, Clinical Trials Center of National Cancer Center

Abstract

Abstract

Personalized medicine (PM) tailors prevention and treatment to individuals based on their unique characteristics. It can improve health outcomes and healthcare sustainability by optimizing resource allocation. The European Union (EU) and China both prioritize PM. The IC2PerMed project aims to facilitate collaboration by developing a PM roadmap. This paper presents the main project’s output, a roadmap for implementing PM in the EU and China, promoting best practice exchange, and addressing potential barriers. We assessed PM in the EU and China by mapping policies, programs, funding mechanisms, and health ecosystems. Three Delphi surveys highlighted 65 priorities, which were synthesized into actions. The study identifies priorities to unlock PM's potential for healthcare transformation and better public health. The roadmap includes structural actions, like enhancing health literacy, fostering intersectoral and international collaboration, continuously reviewing technologies, and facilitating innovation market entry through needs assessment and Health Technology Assessment. Data interoperability and shared standards are critical for creating international platforms, and ethical, social, and regulatory considerations are universal in PM processes. A shared action plan can guide health policy and help policymakers understand the interconnection between healthcare, the economy, and society. By supporting international projects and investing in research and innovation, stakeholders can advance global healthcare.

Publisher

Springer Science and Business Media LLC

Reference48 articles.

1. Personalized medicine and the role of health economics and outcomes research: issues, applications, emerging trends, and future research;O’Donnell JC;Value Health J Int Soc Pharmacoeconomics Outcomes Res,2013

2. Has the revolution arrived?;Collins F;Nature,2010

3. Recommendations for robust and reproducible preclinical research in personalised medicine;Fosse V;BMC Med,2023

4. Precision Medicine and Public Health: New Challenges for Effective and Sustainable Health;Traversi D;J Pers Med,2021

5. Personalised medicine, https://research-and-innovation.ec.europa.eu/research-area/health/personalised-medicine_en (2023, accessed 24 July 2023).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3